Evidence map›Paper›PMID 39936974›Full record

ReviewCells2025

GJA1-20k, a Short Isoform of Connexin43, from Its Discovery to Its Potential Implication in Cancer Progression.

Sarah Fournier, Jonathan Clarhaut, Laurent Cronier, Arnaud Monvoisin

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Beyond the gap: moonlighting functions of connexins in cancer.Cell communication and signaling : CCS · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Connexin-Pannexin duality in glioblastoma.Cell and tissue research · 2026
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sarah FournierLaboratory Channels and Connexins in Cancer and Cell Stemness (4CS), UR 22751, University of Poitiers, 1 Rue Georges Bonnet, TSA 51106, CEDEX 09, 86073 Poitiers, France.ORCID 0009-0004-3118-8867
Jonathan ClarhautPharmacology of Antimicrobial Agents and Antibioresistance (PHAR2), INSERM U1070, University of Poitiers; 1 Rue Georges Bonnet, TSA 51106, CEDEX 09, 86073 Poitiers, France.ORCID 0000-0001-6958-2668
Laurent CronierLaboratory Channels and Connexins in Cancer and Cell Stemness (4CS), UR 22751, University of Poitiers, 1 Rue Georges Bonnet, TSA 51106, CEDEX 09, 86073 Poitiers, France.ORCID 0000-0002-5088-9325
Arnaud MonvoisinLaboratory Channels and Connexins in Cancer and Cell Stemness (4CS), UR 22751, University of Poitiers, 1 Rue Georges Bonnet, TSA 51106, CEDEX 09, 86073 Poitiers, France.ORCID 0000-0002-9915-4872

Funding

La Ligue Contre le Cancer This research was supported by grants from the "Ligue Nationale contre le Cancer" (comités des Deux-Sèvres et de Charente). S. Fournier is recipient of a doctoral fellowship from the "Ministère de l'enseignement supérieur et de la recherche".
6 · The paper itself

Abstract

The Connexin43 transmembrane protein (Cx43), encoded by the

Indexed as

Connexin 43Disease ProgressionNeoplasmsAnimalsGap JunctionsHumansMitochondriaProtein IsoformsConnexin 43GJA1 protein, humanProtein Isoformsalternative translationcancer progressionCx43GJA1-20kmitochondriatrafficking

Identifiers

PMID39936974
PMCPMC11817742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.